The price of Humacyte Inc (NASDAQ:HUMA) shares last traded on Wall Street rose 8.09% to $1.87.
HUMA stock price is now -4.66% away from the 50-day moving average and -57.24% away from the 200-day moving average. The market capitalization of the company currently stands at $290.08M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On December 20, 2024, H.C. Wainwright reiterated its ‘Buy’ rating on the stock by increasing its target price from $12 to quote $15, while ‘Piper Sandler’ rates the stock as ‘Neutral’
In other news, Scheessele William John, Chief Commercial Officer bought 6,493 shares of the company’s stock on Apr 14 ’25. The stock was bought for $9,999 at an average price of $1.54. Upon completion of the transaction, the Chief Commercial Officer now directly owns 22,018 shares in the company, valued at $41173.66. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 10 ’25, CFO and Chief Corp. Deve. Off. Sander Dale A. bought 20,000 shares of the business’s stock. A total of $30,600 was incurred on buying the stock at an average price of $1.53. This leaves the insider owning 40,600 shares of the company worth $75922.0. A total of 18.94% of the company’s stock is owned by insiders.
During the past 12 months, Humacyte Inc has had a low of $1.15 and a high of $9.97. As of last week, the company has a debt-to-equity ratio of 2.28, a current ratio of 3.68, and a quick ratio of 3.28. The fifty day moving average price for HUMA is $1.9614 and a two-hundred day moving average price translates $4.37305 for the stock.
The latest earnings results from Humacyte Inc (NASDAQ: HUMA) was released for 2025-03-31. The net profit margin was -15481.62% and return on equity was -257.38% for HUMA.
